SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 22nd, 2022 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT qualigen therapeutics, inc.Common Stock Purchase Warrant • December 22nd, 2022 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Alpha Capital Anstalt or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Issue Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 22, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), up to 2,500,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
8% SENIOR CONVERTIBLE DEBENTURE DUE DECEMBER 22, 2025Qualigen Therapeutics, Inc. • December 22nd, 2022 • Pharmaceutical preparations • New York
THIS 8% SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 8% Senior Convertible Debentures of Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), having its principal place of business at 2042 Corte de Nogal, Carlsbad, CA 92011, designated as its 8% Senior Convertible Debenture due December 22, 2025 (this debenture, as amended, restated, supplemented or otherwise modified from time to time, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 22nd, 2022 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 22, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser signatory hereto (the “Purchaser”).
